To the best of our knowledge, this is the first study to test cannabinoids such as CBC and CBG in various glioma cell lines, correlating them with molecular docking studies and expression data from the IHC of patients and public human databases, specifically focusing on PINK1 and GPR55 expression. The gene discussed is GPR55; the disease is central nervous system cancer.